- Trials with a EudraCT protocol (151)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
151 result(s) found for: Tissue perfusion.
Displaying page 5 of 8.
EudraCT Number: 2019-004984-31 | Sponsor Protocol Number: DR180133 | Start Date*: 2021-04-21 |
Sponsor Name:CHRU TOURS | ||
Full Title: Nitrous Oxide in Resistant Depression in Elderly Subjects: A Randomized, Double-blind, Comparator Trial | ||
Medical condition: Resistant Depression in the Elderly Subject | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000934-31 | Sponsor Protocol Number: INN-TOP-005 | Start Date*: 2015-07-10 | |||||||||||
Sponsor Name:Innocoll Pharmaceuticals Limited | |||||||||||||
Full Title: A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination with Systemic Antibiotic Therapy in Diabetic Pa... | |||||||||||||
Medical condition: Diabetic Patients with an Infected Foot Ulcer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) AT (Completed) BE (Completed) ES (Completed) SK (Completed) NL (Completed) GB (Completed) PL (Completed) HU (Completed) DK (Completed) LV (Completed) LT (Completed) EE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003185-26 | Sponsor Protocol Number: 2016-NUK-01 | Start Date*: 2016-10-20 | ||||||||||||||||
Sponsor Name:Aarhus University Hospital | ||||||||||||||||||
Full Title: Qualification of 82Rb PET for measurement of tumor perfusion. Uptake in primary prostate cancer vs healthy prostate | ||||||||||||||||||
Medical condition: Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003859-12 | Sponsor Protocol Number: 12-027 | Start Date*: 2013-07-19 | ||||||||||||||||
Sponsor Name:RWTH Aachen University for the Medical Faculty, represented by Clinical Trial Center Aachen (CTC-A) | ||||||||||||||||||
Full Title: Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus | ||||||||||||||||||
Medical condition: patients with type 2 diabetes mellitus and vascular inflammation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001611-37 | Sponsor Protocol Number: T2F12017 | Start Date*: 2019-02-27 |
Sponsor Name:Medical University Vienna, Gender Medicine Unit, Div. of Endocrinology, Dep of Medicine III | ||
Full Title: A 52 week prospective randomized controlled study to investigate the effect of intramuscular testosterone undecanoate supplementation vs placebo on intrahepatic fat content in overweight/obese men ... | ||
Medical condition: hypogonadism, T2DM, prediabetes, overweight, obesity | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005887-14 | Sponsor Protocol Number: B1321003 | Start Date*: 2010-01-12 | |||||||||||
Sponsor Name:Pfizer Ltd. | |||||||||||||
Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS ... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002945-23 | Sponsor Protocol Number: MT203-2004 | Start Date*: 2015-02-18 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd. | |||||||||||||
Full Title: A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs A... | |||||||||||||
Medical condition: Rheumatoid Arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Prematurely Ended) EE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003561-38 | Sponsor Protocol Number: APHP220729 | Start Date*: 2023-08-23 | |||||||||||
Sponsor Name:Assistance publique - Hôpitaux de Paris | |||||||||||||
Full Title: Durvalumab/Tremelimumab in neoadjuvant and adjuvant setting in patients with HCC treated by electroporation ablation in curative intent: French multicenter phase 2 therapeutic DUMELEP trial (DUMELEP) | |||||||||||||
Medical condition: Hepatocellular carcinoma (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000196-24 | Sponsor Protocol Number: 402-C-1504 | Start Date*: 2016-07-04 |
Sponsor Name:Reata Pharmaceuticals, Inc. | ||
Full Title: A STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION | ||
Medical condition: Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (WHO Group I CTD-PAH) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-005219-16 | Sponsor Protocol Number: GE-135-003 | Start Date*: 2010-12-06 |
Sponsor Name:GE Healthcare Ltd | ||
Full Title: A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis via the Expression of avb3 Integrin Receptors by [18F]AH111585 PET Imaging | ||
Medical condition: Adult subjects with Primary or metastatic tumour lesion of one of the following types: high-grade glioma, including GBM, anaplastic astrocytoma, and anaplastic oligodendroglioma; lung cancer, inclu... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002709-36 | Sponsor Protocol Number: AK2017-3 | Start Date*: 2017-11-21 | ||||||||||||||||
Sponsor Name:Rigshospitalet, Department of Physiology, Nuclear Medicine and PET | ||||||||||||||||||
Full Title: Phase II: 68Ga-NODAGA-E[c(RGDyK)]2 Angiogenese PET for imaging angiogenesis in ST-Elevation Myocardial Infarction(STEMI) | ||||||||||||||||||
Medical condition: ST-Elevation Myocardial Infarction (STEMI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-002201-25 | Sponsor Protocol Number: CHDR2007 | Start Date*: 2020-12-14 |
Sponsor Name:Centre for Human Drug Research | ||
Full Title: A two-part (observational and intervention) study to explore disease characteristics of vulvar (pre)malignancies compared to healthy volunteers | ||
Medical condition: lichen sclerosus, vulvar (pre)malignancies | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000540-26 | Sponsor Protocol Number: CVT-CV-002 | Start Date*: 2013-05-12 | |||||||||||
Sponsor Name:CVie Therapeutics Company Limited | |||||||||||||
Full Title: The clinical study of the safety and efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure - A multicenter, randomized, double-blind, placebo controlled, parallel group clinical ... | |||||||||||||
Medical condition: Acute heart failure decompensated | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005841-19 | Sponsor Protocol Number: DT-DP-D3 | Start Date*: 2013-10-10 | |||||||||||
Sponsor Name:DermaTools Biotech GmbH | |||||||||||||
Full Title: A Multicentric, Double Blind, randomised, Comparative Phase III Study of the Efficacy of the new Wound Healing Solution Diperoxochloric acid (DPOCL, DermaPro®) compared to isotonic Sodium Chloride ... | |||||||||||||
Medical condition: Diabetic foot ulcers with mean diameter between 1.5 and 5 cm after débridement (if indicated); wound stage Wagner grade I or II, Armstrong stadium A or C (for Wagner-Armstrong-Classification), trea... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LV (Completed) LT (Completed) HU (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001455-39 | Sponsor Protocol Number: OPN-305-102 | Start Date*: 2012-10-10 | |||||||||||
Sponsor Name:Opsona Therapeutics Ltd | |||||||||||||
Full Title: A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanis... | |||||||||||||
Medical condition: Prevention of Kidney Graft Dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) NL (Completed) GB (Completed) CZ (Completed) AT (Completed) ES (Ongoing) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003408-65 | Sponsor Protocol Number: | Start Date*: 2016-08-26 | ||||||||||||||||
Sponsor Name:University of Edinburgh [...] | ||||||||||||||||||
Full Title: Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial) | ||||||||||||||||||
Medical condition: Heavy menstrual bleeding | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003105-18 | Sponsor Protocol Number: CHDR1732 | Start Date*: 2017-12-13 | |||||||||||
Sponsor Name:Centre for Human Drug Research | |||||||||||||
Full Title: A randomized, placebo-controlled, evaluator-blinded, study to assess the anti-inflammatory effects of topical erythromycin and clindamycin in patients with inflammatory facial acne | |||||||||||||
Medical condition: Acne vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020437-12 | Sponsor Protocol Number: DT-DP-D2b | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:DermaTools Biotech GmbH | |||||||||||||
Full Title: A multicentric, double blind, randomized, comparative Phase II b study of the efficacy of a wound healing solution in patients with diabetic foot ulcer | |||||||||||||
Medical condition: diabetic foot ulcer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004738-27 | Sponsor Protocol Number: A011-09 | Start Date*: 2018-08-15 | |||||||||||
Sponsor Name:Acceleron Pharma Inc. | |||||||||||||
Full Title: A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonar... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-006192-13 | Sponsor Protocol Number: C200-006 | Start Date*: 2006-06-22 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals US, Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ADDITION OF INHALED ILOPROST IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) RECEIVING ORAL SI... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) is a condition that is characterized by increased pulmonary arterial pressure and vascular resistance that can lead to right ventricular failure and death. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) PT (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
